The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis.
about
Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive ReviewMonocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.Selective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor InteractionsCrystal structure of Streptococcus pyogenes EndoS, an immunomodulatory endoglycosidase specific for human IgG antibodiesUse of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis.Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent CytotoxicityStudy of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence.EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils.Bacterial glycosidases in pathogenesis and glycoengineering.EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycansCP40 from Corynebacterium pseudotuberculosis is an endo-β-N-acetylglucosaminidase.Antiphagocytic function of an IgG glycosyl hydrolase from Streptococcus equi subsp. equi and its use as a vaccine componentIgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitisA novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assaysClinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisitaEndoS2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses N-linked glycans on IgG and α1-acid glycoprotein.Liquid-liquid diffusion crystallization improves the X-ray diffraction of EndoS, an endo-β-N-acetylglucosaminidase from Streptococcus pyogenes with activity on human IgGThe carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies.Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory.Targeting B cells and autoantibodies in the therapy of autoimmune diseases.Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita.EndoSd: an IgG glycan hydrolyzing enzyme in Streptococcus dysgalactiae subspecies dysgalactiae.Deglycosylation of mAb by EndoS for improved molecular imaging.Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases.A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice.Generation of a Mutant Mucor hiemalis Endoglycosidase That Acts on Core-fucosylated N-Glycans.Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease.Characterization of novel endo-β-N-acetylglucosaminidases from Sphingobacterium species, Beauveria bassiana and Cordyceps militaris that specifically hydrolyze fucose-containing oligosaccharides and human IgG.Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues.
P2860
Q26773178-D3A806A6-40E7-4111-853A-2A7C381BFDFDQ27314948-53CCBC4E-BFC7-4CDF-9394-409733B529FEQ27678384-9D8B971A-7C86-46E4-8D12-201725210FC7Q27683509-B1A10C20-A60B-4293-BB13-A8DA16EF6359Q33613411-8C788EA5-AE3E-4EE6-B759-624EB4D41906Q33766365-20C9DB8B-A81C-4EF0-9274-5BD5A647E410Q33914405-2637FBEA-4E88-443A-AA27-ECC20B129352Q35087854-EF39535B-837B-46D0-8063-DE2EBF988B0DQ35362348-945D7BAC-12E0-4DDE-A0A7-74613C4C8AFCQ35686671-4D280DED-8BE2-4516-A66A-AEDF305C08D7Q36184582-6608C40A-0F31-4510-BD71-4DBD0F7285E2Q36211146-AFFA7B1F-8706-4310-B74C-6300F93F2947Q36281698-64FBB4EE-7701-45B5-9BF8-7F8D35968659Q36363866-C0E7DE64-41D1-4D43-83B6-2E184C5A27E9Q37055162-ABABAFF2-C977-45C8-AE9D-98AD1CD23317Q37186877-AA7A6120-9D5C-4B12-96C0-6EEB6B0A4F18Q37374699-A529E96E-69DE-497A-967E-46A1CDA860E8Q38117686-8E5EC31E-0C51-452F-A589-60C0F4CE9297Q38155231-06E3017E-FEF6-4370-9DD0-CF0A60197DD5Q38207937-C4EF0861-9823-4979-8A21-CDEF642AA6DFQ38720806-A835F725-38B9-4933-9B1F-2BBBEACA44C2Q38864745-5E87A9DC-8E1F-4809-853E-5205B51A6792Q38964828-940617E5-83DE-48AA-91C4-69656061D05EQ39366396-C7CECFA2-5522-40FD-A6A7-640A249FB077Q40425520-0AD5B722-C565-4CFF-AE74-CBBBEA0E3199Q41593902-CE2A3C19-50A8-4F14-B6C6-0E85870775A3Q42725794-D832629A-2F05-4289-8A8F-B67D0AF514CAQ47220975-1523168C-6B78-4A5F-A6C2-6056FF4A23F3Q49272061-ECDF1EC1-D60C-414B-94FA-085A0A463CF1Q52370705-E777E80E-1A01-4F2E-BB77-D974C9FC4DFE
P2860
The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The IgG-specific endoglycosida ...... mediated autoimmune hemolysis.
@ast
The IgG-specific endoglycosida ...... mediated autoimmune hemolysis.
@en
type
label
The IgG-specific endoglycosida ...... mediated autoimmune hemolysis.
@ast
The IgG-specific endoglycosida ...... mediated autoimmune hemolysis.
@en
prefLabel
The IgG-specific endoglycosida ...... mediated autoimmune hemolysis.
@ast
The IgG-specific endoglycosida ...... mediated autoimmune hemolysis.
@en
P2093
P2860
P1433
P1476
The IgG-specific endoglycosida ...... mediated autoimmune hemolysis.
@en
P2093
Christian Lood
Juana G Briceño
Lucie Baudino
Maria Allhorn
Martin L Olsson
Mattias Collin
Shozo Izui
P2860
P304
P356
10.1182/BLOOD-2009-08-239020
P407
P577
2010-03-31T00:00:00Z